多靶点粪便RNA检测用于结直肠癌筛查
这项3期临床试验(CRC-PREVENT)在8920名45岁及以上平均风险人群中评估了多靶点粪便RNA检测(ColoSense)与结肠镜检查结果对比的性能。该检测对结直肠癌的灵敏度为94%,对进展期腺瘤的灵敏度为46%,无病变特异度为88%,对结直肠癌和进展期腺瘤的灵敏度均显著优于粪便免疫化学检测(FIT)。
要点
- 在45岁及以上人群中,mt-sRNA检测对结直肠癌灵敏度为94%,对进展期腺瘤为46%。
- mt-sRNA检测对结直肠癌灵敏度94% vs FIT 78%(McNemar P = .01),对进展期腺瘤46% vs 29%(McNemar P < .001)。
- mt-sRNA检测无病变特异度为88%,与现有分子诊断检测相当。
核心结论
- 在45岁及以上个体中,mt-sRNA检测对结直肠肿瘤(结直肠癌和进展期腺瘤)显示出高灵敏度,且灵敏度较FIT有显著改善;无病变特异度与现有分子诊断检测相当。
研究设计与样本
- 这项3期临床试验(CRC-PREVENT)是一项盲法、前瞻性、横断面研究,用于支持III类医疗器械的上市前批准申请。
- 共8920名符合条件参与者通过社交媒体平台在线识别,并于2021年6月至2022年6月通过去中心化护士呼叫中心入组。
- 参与者来自美国49个州,在超过3800家内镜中心接受结肠镜检查;所有参与者完成mt-sRNA检测,该检测包含市售粪便免疫化学检测(FIT)、8种RNA转录本浓度和参与者报告的吸烟状态。
- 粪便样本在参与者于当地内镜中心完成结肠镜检查前采集,mt-sRNA检测结果(阳性或阴性)与结肠镜检查所见指数病变进行比较。
主要发现
- 参与者平均(范围)年龄为55(45-90)岁,4%自认为亚裔,11%自认为黑人,7%自认为西班牙裔。
- 在8920名符合条件参与者中,36名(0.40%)患有结直肠癌,606名(6.8%)患有进展期腺瘤。
- mt-sRNA检测对结直肠癌的灵敏度为94%,对进展期腺瘤的灵敏度为46%,结肠镜无病变的特异度为88%。
- 与FIT相比,mt-sRNA检测对结直肠癌灵敏度显著改善(94% vs 78%;McNemar P = .01),对进展期腺瘤灵敏度显著改善(46% vs 29%;McNemar P < .001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Noninvasive tests for colorectal cancer screening must include sensitive detection of colorectal cancer and precancerous lesions. These tests must be validated for the intended-use population, which includes average-risk individuals 45 years or older. OBJECTIVE: To evaluate the sensitivity and specificity of a noninvasive, multitarget stool RNA (mt-sRNA) test (ColoSense) test compared with results from a colonoscopy. DESIGN, SETTING, AND PARTICIPANTS: This phase 3 clinical trial (CRC-PREVENT) was a blinded, prospective, cross-sectional study to support a premarket approval application for a class III medical device. A total of 8920 participants were identified online using social media platforms and enrolled from June 2021 to June 2022 using a decentralized nurse call center. All participants completed the mt-sRNA test, which incorporated a commercially available fecal immunochemical test (FIT), concentration of 8 RNA transcripts, and participant-reported smoking status. Stool samples were collected prior to participants completing a colonoscopy at their local endoscopy center. The mt-sRNA test results (positive or negative) were compared with index lesions observed on colonoscopy. Over the course of 12 months, individuals 45 years and older were enrolled in the clinical trial using the decentralized recruitment strategy. Participants were enrolled from 49 US states and obtained colonoscopies at more than 3800 different endoscopy centers. MAIN OUTCOMES AND MEASURES: The primary outcomes included the sensitivity of the mt-sRNA test for detecting colorectal cancer and advanced adenomas and the specificity for no lesions on colonoscopy. RESULTS: The mean (range) age of participants was 55 (45-90) years, with 4% self-identified as Asian, 11% as Black, and 7% as Hispanic. Of the 8920 eligible participants, 36 (0.40%) had colorectal cancer and 606 (6.8%) had advanced adenomas. The mt-sRNA test sensitivity for detecting colorectal cancer was 94%, sensitivity for detecting advanced adenomas was 46%, and specificity for no lesions on colonoscopy was 88%. The mt-sRNA test showed significant improvement in sensitivity for colorectal cancer (94% vs 78%; McNemar P = .01) and advanced adenomas (46% vs 29%; McNemar P < .001) compared with results of the FIT. CONCLUSIONS AND RELEVANCE: In individuals 45 years and older, the mt-sRNA test showed high sensitivity for colorectal neoplasia (colorectal cancer and advanced adenoma) with significant improvement in sensitivity relative to the FIT. Specificity for no lesions on colonoscopy was comparable to existing molecular diagnostic tests. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04739722.
引用
- Barnell EK, Wurtzler EM, La Rocca J, et al. Multitarget Stool RNA Test for Colorectal Cancer Screening. JAMA. 2023. PMID: 37870871. doi:10.1001/jama.2023.22231
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。